Comparison of Treatment Persistence with Dabigatran or Rivaroxaban versus Vitamin K Antagonist Oral Anticoagulants in Atrial Fibrillation Patients: A Competing Risk Analysis in the French National Health Care Databases.
Géric MauraCécile BillionnetFrançois AllaJoshua J GagneAntoine ParientePublished in: Pharmacotherapy (2017)
Results from this nationwide cohort study showed high non-persistence levels with all OACs and suggest that persistence with both dabigatran and rivaroxaban therapy is not better than persistence with VKA therapy. Hospitalizations for bleeding among non-persistent patients were unlikely to explain these high non-persistence rates.
Keyphrases
- atrial fibrillation
- oral anticoagulants
- end stage renal disease
- healthcare
- ejection fraction
- newly diagnosed
- chronic kidney disease
- left atrial
- catheter ablation
- left atrial appendage
- heart failure
- peritoneal dialysis
- prognostic factors
- venous thromboembolism
- direct oral anticoagulants
- percutaneous coronary intervention
- coronary artery disease
- patient reported outcomes
- pulmonary embolism
- mesenchymal stem cells
- artificial intelligence
- bone marrow
- smoking cessation
- replacement therapy
- big data